Ariad Pharmaceuticals – Advanced Malignancies

Access Program Information

The purpose of this study is to provide brigatinib for those patients with locally advanced
and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their
inability to meet eligibility criteria for on-going recruiting trials, inability to
participate in other clinical trials (e.g., poor performance status, lack of geographic
proximity), or because other medical interventions are not considered appropriate or